X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4413) 4413
Publication (440) 440
Newsletter (74) 74
Book Review (34) 34
Book Chapter (13) 13
Newspaper Article (6) 6
Conference Proceeding (3) 3
Dissertation (3) 3
Magazine Article (2) 2
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fludarabine (3669) 3669
humans (3144) 3144
hematology (2178) 2178
oncology (1925) 1925
male (1905) 1905
index medicus (1853) 1853
female (1807) 1807
middle aged (1651) 1651
aged (1382) 1382
adult (1288) 1288
vidarabine - analogs & derivatives (1260) 1260
cyclophosphamide (1012) 1012
rituximab (1012) 1012
leukemia, lymphocytic, chronic, b-cell - drug therapy (984) 984
treatment outcome (861) 861
chronic lymphocytic leukemia (860) 860
therapy (829) 829
antineoplastic combined chemotherapy protocols - therapeutic use (773) 773
transplantation (763) 763
chronic lymphocytic-leukemia (676) 676
cancer (629) 629
chemotherapy (623) 623
vidarabine - administration & dosage (605) 605
leukemia (579) 579
antineoplastic agents - therapeutic use (574) 574
aged, 80 and over (512) 512
care and treatment (492) 492
cll (475) 475
immunology (470) 470
prognosis (459) 459
vidarabine - therapeutic use (458) 458
survival (420) 420
adolescent (416) 416
bone-marrow-transplantation (405) 405
leukemia, lymphocytic, chronic, b-cell - pathology (404) 404
stem-cell transplantation (399) 399
disease-free survival (388) 388
stem cells (378) 378
alemtuzumab (365) 365
retrospective studies (364) 364
transplantation conditioning - methods (362) 362
research (356) 356
health aspects (339) 339
hematopoietic stem cells (337) 337
lymphoma (337) 337
transplantation, homologous (332) 332
risk factors (329) 329
cyclophosphamide - administration & dosage (318) 318
apoptosis (310) 310
antineoplastic combined chemotherapy protocols - adverse effects (305) 305
remission induction (305) 305
survival analysis (305) 305
survival rate (304) 304
trial (301) 301
hematology, oncology and palliative medicine (298) 298
vidarabine - adverse effects (298) 298
recurrence (295) 295
hematopoietic stem cell transplantation (291) 291
leukemia, lymphocytic, chronic, b-cell - mortality (287) 287
chlorambucil (280) 280
medicine & public health (276) 276
fludarabine plus cyclophosphamide (267) 267
non-hodgkins-lymphoma (267) 267
antineoplastic agents - adverse effects (262) 262
drug therapy (262) 262
follow-up studies (260) 260
leukemia, lymphocytic, chronic, b-cell - therapy (260) 260
stem cell transplantation (259) 259
child (257) 257
analysis (256) 256
antineoplastic agents (256) 256
dosage and administration (255) 255
antibodies, monoclonal - therapeutic use (251) 251
young adult (250) 250
hematopoietic stem cell transplantation - methods (242) 242
leukemia, lymphocytic, chronic, b-cell - genetics (241) 241
diagnosis (240) 240
pharmacology & pharmacy (239) 239
article (235) 235
busulfan (234) 234
acute myeloid-leukemia (229) 229
versus-host-disease (228) 228
antineoplastic combined chemotherapy protocols - administration & dosage (227) 227
antimitotic agents (225) 225
cladribine (221) 221
patients (218) 218
phase-ii trial (218) 218
toxicity (215) 215
animals (206) 206
expression (206) 206
initial therapy (204) 204
hemic and lymphatic diseases (201) 201
combination (199) 199
regimen (199) 199
antineoplastic agents - pharmacology (198) 198
vidarabine - pharmacology (192) 192
bone marrow (191) 191
immunotherapy (191) 191
lymphomas (191) 191
chemoimmunotherapy (187) 187
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4359) 4359
French (33) 33
German (32) 32
Polish (18) 18
Russian (18) 18
Spanish (14) 14
Czech (7) 7
Hungarian (6) 6
Korean (6) 6
Chinese (4) 4
Portuguese (3) 3
Slovak (3) 3
Turkish (3) 3
Japanese (2) 2
Romanian (2) 2
Slovenian (2) 2
Dutch (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Eye (Basingstoke), ISSN 0950-222X, 2019, Volume 33, Issue 6, pp. 1023 - 1025
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 04/2019, Volume 12, Issue 1, pp. 44 - 10
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2014, Volume 32, Issue 12, pp. 1236 - 1236
Purpose Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based... 
TRIAL | THERAPY | ONCOLOGY | CYCLOPHOSPHAMIDE | FLUDARABINE | PREVIOUSLY UNTREATED PATIENTS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2019, Volume 184, Issue 3, pp. 322 - 322
Journal Article
Leukemia, ISSN 0887-6924, 08/2000, Volume 14, Issue 8, pp. 1405 - 1413
Fludarabine is a nucleotide analog effective in the clinical treatment of chronic lymphocytic leukemia (CLL) and other indolent lymphocytic malignancies.... 
fludarabine
Journal Article
Blood, ISSN 0006-4971, 04/2018, Volume 131, Issue 17, pp. 1910 - 1919
We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naive (TN) older patients (>= 65 years of age)... 
BENDAMUSTINE | MULTICENTER | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | INITIAL THERAPY | OPEN-LABEL | CLL8 TRIAL | HEMATOLOGY | CHLORAMBUCIL | PREVIOUSLY UNTREATED PATIENTS | Clinical Trials and Observations
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 15, pp. 1568 - 1572
Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton's tyrosine kinase inhibitor ibrutinib, and B-cell... 
ANTIBODIES | OPEN-LABEL | THERAPY | HEMATOLOGY | FLUDARABINE | RITUXIMAB | 8 | 12 | Clinical Trials and Observations | 39
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 15, pp. 1547 - 1548
In this issue of Blood, Rogers et al demonstrate that 3 novel agents approved for chronic lymphocytic leukemia (CLL), ibrutinib, venetoclax, and obinutuzumab,... 
HEMATOLOGY | CYCLOPHOSPHAMIDE | FLUDARABINE | VENETOCLAX | RITUXIMAB
Journal Article
Blood, ISSN 0006-4971, 03/2004, Volume 103, Issue 6, pp. 2027 - 2031
Alemtuzumab therapy is effective for some refractory chronic lymphocytic leukemia (CLL), but identifying responders requires at least 8 weeks of therapy. Early... 
HEMATOLOGY | CAMPATH-1H | FLUDARABINE
Journal Article
BLOOD, ISSN 0006-4971, 06/2012, Volume 119, Issue 23, pp. 5591 - 5598
We report the relative efficacy of coinfusing 2 umbilical cord blood units (dUCB) compared with peripheral blood progenitor cells (PBPCs) from 8 of 8 or 7 of 8... 
ADULT PATIENTS | ENGRAFTMENT | BONE-MARROW | MALIGNANCIES | UMBILICAL-CORD BLOOD | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | FLUDARABINE
Journal Article
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, ISSN 1083-8791, 08/2019
Despite excellent transplant outcomes of aplastic anemia (AA) in developed countries, management in developing countries is challenging because of delay in the... 
Journal Article
BLOOD, ISSN 0006-4971, 07/2017, Volume 130, Issue 3, pp. 376 - 376
Journal Article
Cancer, ISSN 0008-543X, 11/2013, Volume 119, Issue 21, pp. 3805 - 3811
BACKGROUNDThe combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with... 
chronic lymphocytic leukemia | combination of fludarabine, cyclophosphamide, and rituximab | cytopenia | prognosis | and rituximab | CHEMOIMMUNOTHERAPY | combination of fludarabine | REGIMEN | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROME | TRIAL | MAINTENANCE | ONCOLOGY | INITIAL THERAPY | cyclophosphamide | COMBINATION CHEMOTHERAPY | PROGRESSION-FREE | LYMPHOMA | Myeloablative Agonists - therapeutic use | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Young Adult | Aged, 80 and over | Clinical Trials, Phase II as Topic - statistics & numerical data | Adult | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Retrospective Studies | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Immune Tolerance - drug effects | Pancytopenia - chemically induced | Vidarabine - adverse effects | Pancytopenia - diagnosis | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Immunotherapy - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Pancytopenia - epidemiology | Adolescent | Aged | Vidarabine - administration & dosage | Pancytopenia - blood | Antibodies, Monoclonal, Murine-Derived - adverse effects | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 03/2001, Volume 41, Issue 1-2, pp. 137 - 145
Follicular small cell and follicular mixed small and large cell lymphoma (FL) are incurable with conventional chemotherapy, and generally follow a relapsing... 
fludarabine
Journal Article
BLOOD, ISSN 0006-4971, 06/2019, Volume 133, Issue 26, pp. 2765 - 2775
This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and... 
17P DELETION | CLL | THERAPY | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | OPEN-LABEL | OUTCOMES | INHIBITOR | HEMATOLOGY | FLUDARABINE | Lymphoid Neoplasia
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.